Regosarc: regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-a quality-adjusted time without symptoms of progression or toxicity analysis

Autor: Berry, V. (Vincent), Basson, L. (Laurent), Bogart, E. (Emilie), Mir, O. (Olivier), Blay, J-Y. (Jean-Yves), Italiano, A. (Antoine), Bertucci, F. (François), Chevreau, C. (Christine), Clisant-Delaine, S. (Stephanie), Liegl-Atzwanger, B. (Bernadette), Tresch-Bruneel, E. (Emmanuelle), Wallet, J. (Jennifer), Taieb, S. (Sophie), Decoupigny, E. (Emilie), Le Cesne, A. (Axel), Brodowicz, T. (Thomas), Penel, N. (Nicolas)

Publikováno v: Cancer
Cancer, 2017, Cancer, 123, pp.2294-2302. ⟨10.1002/cncr.30661⟩
Cancer, Wiley, 2017, Cancer, 123, pp.2294-2302. ⟨10.1002/cncr.30661⟩

International audience; BACKGROUND: In a placebo-controlled, randomized phase 2 trial (ClinicalTrials.gov identifier NCT01900743), regorafenib improved progression-free survival (PFS) for patients with doxorubicin-pretreated advanced nonadipocytic sa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::37812ebfcfde86f4545368c35980e0ea
https://hal.univ-lille.fr/hal-02638646/file/cncr.30661.pdf